JP2015512047A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512047A5
JP2015512047A5 JP2014560404A JP2014560404A JP2015512047A5 JP 2015512047 A5 JP2015512047 A5 JP 2015512047A5 JP 2014560404 A JP2014560404 A JP 2014560404A JP 2014560404 A JP2014560404 A JP 2014560404A JP 2015512047 A5 JP2015512047 A5 JP 2015512047A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560404A
Other languages
Japanese (ja)
Other versions
JP2015512047A (ja
JP6290795B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054800 external-priority patent/WO2013132089A2/en
Publication of JP2015512047A publication Critical patent/JP2015512047A/ja
Publication of JP2015512047A5 publication Critical patent/JP2015512047A5/ja
Application granted granted Critical
Publication of JP6290795B2 publication Critical patent/JP6290795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560404A 2012-03-08 2013-03-08 女性の対象が癌に罹患するリスクを予測する方法、あるいは対象の癌を診断する方法 Active JP6290795B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261608346P 2012-03-08 2012-03-08
EP12158679 2012-03-08
US61/608,346 2012-03-08
EP12158679.6 2012-03-08
EP12165054.3 2012-04-20
EP12165054 2012-04-20
PCT/EP2013/054800 WO2013132089A2 (en) 2012-03-08 2013-03-08 A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Publications (3)

Publication Number Publication Date
JP2015512047A JP2015512047A (ja) 2015-04-23
JP2015512047A5 true JP2015512047A5 (enExample) 2015-11-05
JP6290795B2 JP6290795B2 (ja) 2018-03-07

Family

ID=49117445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560404A Active JP6290795B2 (ja) 2012-03-08 2013-03-08 女性の対象が癌に罹患するリスクを予測する方法、あるいは対象の癌を診断する方法

Country Status (7)

Country Link
US (2) US20150031144A1 (enExample)
EP (1) EP2823313B1 (enExample)
JP (1) JP6290795B2 (enExample)
CN (1) CN103308689B (enExample)
IN (1) IN2014MN01936A (enExample)
RU (1) RU2642623C2 (enExample)
WO (1) WO2013132089A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101596A2 (en) 2013-12-30 2015-07-09 Oncoprevent Gmbh Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
CN104237535B (zh) * 2014-09-30 2016-02-10 天津市泌尿外科研究所 神经降压素在诊断去势抵抗性前列腺癌神经内分泌化亚型和判断预后中的应用
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
RU2745751C2 (ru) * 2015-02-27 2021-03-31 Сфинготек Гмбх Способ прогнозирования риска развития ожирения у субъекта
KR102618553B1 (ko) * 2022-08-31 2023-12-27 숙명여자대학교산학협력단 당뇨병 환자의 유방암 발병 예측 및 유방암 환자의 예후 예측용 바이오마커

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
ES2544954T3 (es) * 2006-02-14 2015-09-07 Universita' Degli Studi Di Siena Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
US8449864B2 (en) * 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
WO2009044561A1 (ja) * 2007-10-03 2009-04-09 Shizuoka Prefecture 抗proNT/NMNモノクローナル抗体
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーPieris Ag IL−4Rαに結合する涙液リポカリンムテイン
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CA2886814C (en) * 2012-10-02 2021-09-07 Sphingotec Gmbh A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Similar Documents

Publication Publication Date Title
BR112016010442A2 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112014021878A2 (enExample)
BR112014017901A2 (enExample)
BR112014019204A2 (enExample)
BR112015015948A2 (enExample)
BR112016004712A2 (enExample)
BR112014017722A2 (enExample)
BR112016014216A2 (enExample)
BR112016003237A2 (enExample)
BR112016002115A2 (enExample)
BR112014017653A2 (enExample)
BR112014017794A2 (enExample)
BR112016004773A2 (enExample)
BR112014017601A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)